Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 131

1.

Influence of UGT1A1 and SLCO1B1 Polymorphisms and Efavirenz on Bilirubin Disposition in Healthy Volunteers.

Collins KS, Metzger IF, Gufford BT, Lu J, Medeiros EB, Pratt VM, Skaar TC, Desta Z.

Drug Metab Dispos. 2019 Dec 30. pii: dmd.119.089052. doi: 10.1124/dmd.119.089052. [Epub ahead of print]

2.

RegSNPs-intron: a computational framework for predicting pathogenic impact of intronic single nucleotide variants.

Lin H, Hargreaves KA, Li R, Reiter JL, Wang Y, Mort M, Cooper DN, Zhou Y, Zhang C, Eadon MT, Dolan ME, Ipe J, Skaar TC, Liu Y.

Genome Biol. 2019 Nov 28;20(1):254. doi: 10.1186/s13059-019-1847-4.

3.

A Call for Clear and Consistent Communications Regarding the Role of Pharmacogenetics in Antidepressant Pharmacotherapy.

Hicks JK, Bishop JR, Gammal RS, Sangkuhl K, Bousman CA, Leeder JS, Llerena A, Mueller DJ, Ramsey LB, Scott SA, Skaar TC, Caudle KE, Klein TE, Gaedigk A.

Clin Pharmacol Ther. 2020 Jan;107(1):50-52. doi: 10.1002/cpt.1661. Epub 2019 Oct 30. No abstract available.

PMID:
31664715
4.

MicroRNA 362-3p Reduces hERG-related Current and Inhibits Breast Cancer Cells Proliferation.

Assiri AA, Mourad N, Shao M, Kiel P, Liu W, Skaar TC, Overholser BR.

Cancer Genomics Proteomics. 2019 Nov-Dec;16(6):433-442. doi: 10.21873/cgp.20147.

5.

Allele-specific expression and high-throughput reporter assay reveal functional genetic variants associated with alcohol use disorders.

Rao X, Thapa KS, Chen AB, Lin H, Gao H, Reiter JL, Hargreaves KA, Ipe J, Lai D, Xuei X, Wang Y, Gu H, Kapoor M, Farris SP, Tischfield J, Foroud T, Goate AM, Skaar TC, Mayfield RD, Edenberg HJ, Liu Y.

Mol Psychiatry. 2019 Sep 2. doi: 10.1038/s41380-019-0508-z. [Epub ahead of print]

PMID:
31477794
6.

Effects of SLCO1B1 polymorphisms on plasma estrogen concentrations in women with breast cancer receiving aromatase inhibitors exemestane and letrozole.

Dempsey JM, Kidwell KM, Gersch CL, Pesch AM, Desta Z, Storniolo AM, Stearns V, Skaar TC, Hayes DF, Henry NL, Rae JM, Hertz DL.

Pharmacogenomics. 2019 Jun;20(8):571-580. doi: 10.2217/pgs-2019-0020.

PMID:
31190621
7.

Multi-site investigation of strategies for the clinical implementation of CYP2D6 genotyping to guide drug prescribing.

Cavallari LH, Van Driest SL, Prows CA, Bishop JR, Limdi NA, Pratt VM, Ramsey LB, Smith DM, Tuteja S, Duong BQ, Hicks JK, Lee JC, Obeng AO, Beitelshees AL, Bell GC, Blake K, Crona DJ, Dressler L, Gregg RA, Hines LJ, Scott SA, Shelton RC, Weitzel KW, Johnson JA, Peterson JF, Empey PE, Skaar TC; IGNITE Network.

Genet Med. 2019 Oct;21(10):2255-2263. doi: 10.1038/s41436-019-0484-3. Epub 2019 Mar 21.

8.

Analytical Validation of Variants to Aid in Genotype-Guided Therapy for Oncology.

Swart M, Stansberry WM, Pratt VM, Medeiros EB, Kiel PJ, Shen F, Schneider BP, Skaar TC.

J Mol Diagn. 2019 May;21(3):491-502. doi: 10.1016/j.jmoldx.2019.01.009. Epub 2019 Feb 20.

PMID:
30794985
9.

Drug-gene and drug-drug interactions associated with tramadol and codeine therapy in the INGENIOUS trial.

Fulton CR, Zang Y, Desta Z, Rosenman MB, Holmes AM, Decker BS, Zhang Y, T Callaghan J, Pratt VM, Levy KD, Gufford BT, Dexter PR, Skaar TC, Eadon MT.

Pharmacogenomics. 2019 Apr;20(6):397-408. doi: 10.2217/pgs-2018-0205. Epub 2019 Feb 20.

PMID:
30784356
10.

Analytical validity of a genotyping assay for use with personalized antihypertensive and chronic kidney disease therapy.

Collins KS, Pratt VM, Stansberry WM, Medeiros EB, Kannegolla K, Swart M, Skaar TC, Chapman AB, Decker BS, Moorthi RN, Eadon MT.

Pharmacogenet Genomics. 2019 Jan;29(1):18-22. doi: 10.1097/FPC.0000000000000361.

11.

Qualitative study of system-level factors related to genomic implementation.

Zebrowski AM, Ellis DE, Barg FK, Sperber NR, Bernhardt BA, Denny JC, Dexter PR, Ginsburg GS, Horowitz CR, Johnson JA, Levy MA, Orlando LA, Pollin TI, Skaar TC, Kimmel SE.

Genet Med. 2019 Jul;21(7):1534-1540. doi: 10.1038/s41436-018-0378-9. Epub 2018 Nov 23.

12.

Report of Confirmation of the rs7853758 and rs885004 Haplotype in SLC28A3.

Stansberry WM, Swart M, Medeiros EB, Skaar TC, Pratt VM.

Genet Test Mol Biomarkers. 2018 Nov;22(11):652-655. doi: 10.1089/gtmb.2018.0194. Epub 2018 Oct 23.

13.

Next generation MicroRNA sequencing to identify coronary artery disease patients at risk of recurrent myocardial infarction.

Kanuri SH, Ipe J, Kassab K, Gao H, Liu Y, Skaar TC, Kreutz RP.

Atherosclerosis. 2018 Nov;278:232-239. doi: 10.1016/j.atherosclerosis.2018.09.021. Epub 2018 Oct 3.

14.

PASSPORT-seq: A Novel High-Throughput Bioassay to Functionally Test Polymorphisms in Micro-RNA Target Sites.

Ipe J, Collins KS, Hao Y, Gao H, Bhatia P, Gaedigk A, Liu Y, Skaar TC.

Front Genet. 2018 Jun 15;9:219. doi: 10.3389/fgene.2018.00219. eCollection 2018.

15.

Rifampin modulation of xeno- and endobiotic conjugating enzyme mRNA expression and associated microRNAs in human hepatocytes.

Gufford BT, Robarge JD, Eadon MT, Gao H, Lin H, Liu Y, Desta Z, Skaar TC.

Pharmacol Res Perspect. 2018 Mar 26;6(2):e00386. doi: 10.1002/prp2.386. eCollection 2018 Apr.

16.

Allelic decomposition and exact genotyping of highly polymorphic and structurally variant genes.

Numanagić I, Malikić S, Ford M, Qin X, Toji L, Radovich M, Skaar TC, Pratt VM, Berger B, Scherer S, Sahinalp SC.

Nat Commun. 2018 Feb 26;9(1):828. doi: 10.1038/s41467-018-03273-1.

17.

CYP2D6 and Endoxifen in Tamoxifen Therapy: A Tribute to David A. Flockhart.

Skaar TC, Desta Z.

Clin Pharmacol Ther. 2018 May;103(5):755-757. doi: 10.1002/cpt.1039. Epub 2018 Feb 23.

PMID:
29473149
18.

Research Directions in the Clinical Implementation of Pharmacogenomics: An Overview of US Programs and Projects.

Volpi S, Bult CJ, Chisholm RL, Deverka PA, Ginsburg GS, Jacob HJ, Kasapi M, McLeod HL, Roden DM, Williams MS, Green ED, Rodriguez LL, Aronson S, Cavallari LH, Denny JC, Dressler LG, Johnson JA, Klein TE, Leeder JS, Piquette-Miller M, Perera M, Rasmussen-Torvik LJ, Rehm HL, Ritchie MD, Skaar TC, Wagle N, Weinshilboum R, Weitzel KW, Wildin R, Wilson J, Manolio TA, Relling MV.

Clin Pharmacol Ther. 2018 May;103(5):778-786. doi: 10.1002/cpt.1048. Epub 2018 Mar 30. Review.

19.

In Vivo siRNA Delivery and Rebound of Renal LRP2 in Mice.

Eadon MT, Cheng YH, Hato T, Benson EA, Ipe J, Collins KS, De Luca T, El-Achkar TM, Bacallao RL, Skaar TC, Dagher PC.

J Drug Deliv. 2017;2017:4070793. doi: 10.1155/2017/4070793. Epub 2017 Dec 20.

20.

Multisite Investigation of Strategies for the Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy.

Empey PE, Stevenson JM, Tuteja S, Weitzel KW, Angiolillo DJ, Beitelshees AL, Coons JC, Duarte JD, Franchi F, Jeng LJB, Johnson JA, Kreutz RP, Limdi NA, Maloney KA, Owusu Obeng A, Peterson JF, Petry N, Pratt VM, Rollini F, Scott SA, Skaar TC, Vesely MR, Stouffer GA, Wilke RA, Cavallari LH, Lee CR; IGNITE Network.

Clin Pharmacol Ther. 2018 Oct;104(4):664-674. doi: 10.1002/cpt.1006. Epub 2018 Jan 30.

21.

Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.

Cavallari LH, Lee CR, Beitelshees AL, Cooper-DeHoff RM, Duarte JD, Voora D, Kimmel SE, McDonough CW, Gong Y, Dave CV, Pratt VM, Alestock TD, Anderson RD, Alsip J, Ardati AK, Brott BC, Brown L, Chumnumwat S, Clare-Salzler MJ, Coons JC, Denny JC, Dillon C, Elsey AR, Hamadeh IS, Harada S, Hillegass WB, Hines L, Horenstein RB, Howell LA, Jeng LJB, Kelemen MD, Lee YM, Magvanjav O, Montasser M, Nelson DR, Nutescu EA, Nwaba DC, Pakyz RE, Palmer K, Peterson JF, Pollin TI, Quinn AH, Robinson SW, Schub J, Skaar TC, Smith DM, Sriramoju VB, Starostik P, Stys TP, Stevenson JM, Varunok N, Vesely MR, Wake DT, Weck KE, Weitzel KW, Wilke RA, Willig J, Zhao RY, Kreutz RP, Stouffer GA, Empey PE, Limdi NA, Shuldiner AR, Winterstein AG, Johnson JA; IGNITE Network.

JACC Cardiovasc Interv. 2018 Jan 22;11(2):181-191. doi: 10.1016/j.jcin.2017.07.022. Epub 2017 Nov 1.

22.

Variants in the CYP2B6 3'UTR Alter In Vitro and In Vivo CYP2B6 Activity: Potential Role of MicroRNAs.

Burgess KS, Ipe J, Swart M, Metzger IF, Lu J, Gufford BT, Thong N, Desta Z, Gaedigk R, Pearce RE, Gaedigk A, Liu Y, Skaar TC.

Clin Pharmacol Ther. 2018 Jul;104(1):130-138. doi: 10.1002/cpt.892. Epub 2017 Oct 25.

23.

CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study.

Hertz DL, Kidwell KM, Hilsenbeck SG, Oesterreich S, Osborne CK, Philips S, Chenault C, Hartmaier RJ, Skaar TC, Sikora MJ, Rae JM.

Breast Cancer Res Treat. 2017 Nov;166(1):277-287. doi: 10.1007/s10549-017-4400-8. Epub 2017 Jul 20.

24.

Variable aromatase inhibitor plasma concentrations do not correlate with circulating estrogen concentrations in post-menopausal breast cancer patients.

Hertz DL, Speth KA, Kidwell KM, Gersch CL, Desta Z, Storniolo AM, Stearns V, Skaar TC, Hayes DF, Henry NL, Rae JM.

Breast Cancer Res Treat. 2017 Oct;165(3):659-668. doi: 10.1007/s10549-017-4346-x. Epub 2017 Jun 22.

25.

Common genetic polymorphisms of adenosine A2A receptor do not influence response to regadenoson.

Berlacher M, Mastouri R, Philips S, Skaar TC, Kreutz RP.

Pharmacogenomics. 2017 Apr;18(6):523-529. doi: 10.2217/pgs-2016-0178. Epub 2017 Mar 30.

26.

Genetic Variants Contributing to Colistin Cytotoxicity: Identification of TGIF1 and HOXD10 Using a Population Genomics Approach.

Eadon MT, Hause RJ, Stark AL, Cheng YH, Wheeler HE, Burgess KS, Benson EA, Cunningham PN, Bacallao RL, Dagher PC, Skaar TC, Dolan ME.

Int J Mol Sci. 2017 Mar 18;18(3). pii: E661. doi: 10.3390/ijms18030661.

27.

Adherence and Tolerability of Alzheimer's Disease Medications: A Pragmatic Randomized Trial.

Campbell NL, Perkins AJ, Gao S, Skaar TC, Li L, Hendrie HC, Fowler N, Callahan CM, Boustani MA.

J Am Geriatr Soc. 2017 Jul;65(7):1497-1504. doi: 10.1111/jgs.14827. Epub 2017 Mar 14.

28.

The IGNITE Pharmacogenetics Working Group: An Opportunity for Building Evidence with Pharmacogenetic Implementation in a Real-World Setting.

Cavallari LH, Beitelshees AL, Blake KV, Dressler LG, Duarte JD, Elsey A, Eichmeyer JN, Empey PE, Franciosi JP, Hicks JK, Holmes AM, Jeng L, Lee CR, Lima JJ, Limdi NA, Modlin J, Obeng AO, Petry N, Pratt VM, Skaar TC, Tuteja S, Voora D, Wagner M, Weitzel KW, Wilke RA, Peterson JF, Johnson JA.

Clin Transl Sci. 2017 May;10(3):143-146. doi: 10.1111/cts.12456. Epub 2017 Mar 14. Review. No abstract available.

29.

High-Throughput Assays to Assess the Functional Impact of Genetic Variants: A Road Towards Genomic-Driven Medicine.

Ipe J, Swart M, Burgess KS, Skaar TC.

Clin Transl Sci. 2017 Mar;10(2):67-77. doi: 10.1111/cts.12440. Epub 2017 Feb 18. Review. No abstract available.

30.

Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update.

Hicks JK, Sangkuhl K, Swen JJ, Ellingrod VL, Müller DJ, Shimoda K, Bishop JR, Kharasch ED, Skaar TC, Gaedigk A, Dunnenberger HM, Klein TE, Caudle KE, Stingl JC.

Clin Pharmacol Ther. 2017 Jul;102(1):37-44. doi: 10.1002/cpt.597. Epub 2017 Feb 13. No abstract available.

31.

Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer.

Robarge JD, Desta Z, Nguyen AT, Li L, Hertz D, Rae JM, Hayes DF, Storniolo AM, Stearns V, Flockhart DA, Skaar TC, Henry NL.

Breast Cancer Res Treat. 2017 Feb;161(3):453-461. doi: 10.1007/s10549-016-4077-4. Epub 2016 Dec 9.

32.

Population Pharmacokinetic Modeling To Estimate the Contributions of Genetic and Nongenetic Factors to Efavirenz Disposition.

Robarge JD, Metzger IF, Lu J, Thong N, Skaar TC, Desta Z, Bies RR.

Antimicrob Agents Chemother. 2016 Dec 27;61(1). pii: e01813-16. doi: 10.1128/AAC.01813-16. Print 2017 Jan.

33.

A new Suzuki synthesis of triphenylethylenes that inhibit aromatase and bind to estrogen receptors α and β.

Zhao LM, Jin HS, Liu J, Skaar TC, Ipe J, Lv W, Flockhart DA, Cushman M.

Bioorg Med Chem. 2016 Nov 1;24(21):5400-5409. doi: 10.1016/j.bmc.2016.08.064. Epub 2016 Aug 31.

34.

Inhibition of Cytochrome P450 2B6 Activity by Voriconazole Profiled Using Efavirenz Disposition in Healthy Volunteers.

Desta Z, Metzger IF, Thong N, Lu JB, Callaghan JT, Skaar TC, Flockhart DA, Galinsky RE.

Antimicrob Agents Chemother. 2016 Oct 21;60(11):6813-6822. doi: 10.1128/AAC.01000-16. Print 2016 Nov.

35.

Identification of rifampin-regulated functional modules and related microRNAs in human hepatocytes based on the protein interaction network.

Li J, Wang Y, Wang L, Dai X, Cong W, Feng W, Xu C, Deng Y, Wang Y, Skaar TC, Liang H, Liu Y.

BMC Genomics. 2016 Aug 22;17 Suppl 7:517. doi: 10.1186/s12864-016-2909-6.

36.

Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in postmenopausal patients with breast cancer.

Hertz DL, Kidwell KM, Seewald NJ, Gersch CL, Desta Z, Flockhart DA, Storniolo AM, Stearns V, Skaar TC, Hayes DF, Henry NL, Rae JM.

Pharmacogenomics J. 2017 Dec;17(6):521-527. doi: 10.1038/tpj.2016.60. Epub 2016 Aug 23.

37.

ESR1 and PGR polymorphisms are associated with estrogen and progesterone receptor expression in breast tumors.

Hertz DL, Henry NL, Kidwell KM, Thomas D, Goddard A, Azzouz F, Speth K, Li L, Banerjee M, Thibert JN, Kleer CG, Stearns V, Hayes DF, Skaar TC, Rae JM.

Physiol Genomics. 2016 Sep 1;48(9):688-98. doi: 10.1152/physiolgenomics.00065.2016. Epub 2016 Aug 19.

38.

Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers.

Radovich M, Kiel PJ, Nance SM, Niland EE, Parsley ME, Ferguson ME, Jiang G, Ammakkanavar NR, Einhorn LH, Cheng L, Nassiri M, Davidson DD, Rushing DA, Loehrer PJ, Pili R, Hanna N, Callaghan JT, Skaar TC, Helft PR, Shahda S, O'Neil BH, Schneider BP.

Oncotarget. 2016 Aug 30;7(35):56491-56500. doi: 10.18632/oncotarget.10606.

39.

Rifampin Regulation of Drug Transporters Gene Expression and the Association of MicroRNAs in Human Hepatocytes.

Benson EA, Eadon MT, Desta Z, Liu Y, Lin H, Burgess KS, Segar MW, Gaedigk A, Skaar TC.

Front Pharmacol. 2016 Apr 26;7:111. doi: 10.3389/fphar.2016.00111. eCollection 2016.

40.

Sleep disorders in breast cancer survivors.

Otte JL, Davis L, Carpenter JS, Krier C, Skaar TC, Rand KL, Weaver M, Landis C, Chernyak Y, Manchanda S.

Support Care Cancer. 2016 Oct;24(10):4197-205. doi: 10.1007/s00520-016-3247-6. Epub 2016 May 4.

PMID:
27146391
41.

Rifampin enhances cytochrome P450 (CYP) 2B6-mediated efavirenz 8-hydroxylation in healthy volunteers.

Cho DY, Shen JH, Lemler SM, Skaar TC, Li L, Blievernicht J, Zanger UM, Kim KB, Shin JG, Flockhart DA, Desta Z.

Drug Metab Pharmacokinet. 2016 Apr;31(2):107-16. doi: 10.1016/j.dmpk.2015.07.002. Epub 2015 Jul 29.

42.

Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer.

Kadakia KC, Snyder CF, Kidwell KM, Seewald NJ, Flockhart DA, Skaar TC, Desta Z, Rae JM, Otte JL, Carpenter JS, Storniolo AM, Hayes DF, Stearns V, Henry NL.

Oncologist. 2016 May;21(5):539-46. doi: 10.1634/theoncologist.2015-0349. Epub 2016 Mar 23.

43.

Implementation of a pharmacogenomics consult service to support the INGENIOUS trial.

Eadon MT, Desta Z, Levy KD, Decker BS, Pierson RC, Pratt VM, Callaghan JT, Rosenman MB, Carpenter JS, Holmes AM, McDonald CA, Benson EA, Patil AS, Vuppalanchi R, Gufford BT, Dave N, Robarge JD, Hyder MA, Haas DM, Kreutz RP, Dexter PR, Skaar TC, Flockhart DA.

Clin Pharmacol Ther. 2016 Jul;100(1):63-6. doi: 10.1002/cpt.347. Epub 2016 Mar 31. Review.

44.

Synthesis of Triphenylethylene Bisphenols as Aromatase Inhibitors That Also Modulate Estrogen Receptors.

Lv W, Liu J, Skaar TC, O'Neill E, Yu G, Flockhart DA, Cushman M.

J Med Chem. 2016 Jan 14;59(1):157-70. doi: 10.1021/acs.jmedchem.5b01677. Epub 2015 Dec 24.

45.

AMPD1 polymorphism and response to regadenoson.

Saab R, Zouk AN, Mastouri R, Skaar TC, Philips S, Kreutz RP.

Pharmacogenomics. 2015 Nov;16(16):1807-15. doi: 10.2217/pgs.15.116. Epub 2015 Nov 10.

46.

Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover.

Oesterreich S, Henry NL, Kidwell KM, Van Poznak CH, Skaar TC, Dantzer J, Li L, Hangartner TN, Peacock M, Nguyen AT, Rae JM, Desta Z, Philips S, Storniolo AM, Stearns V, Hayes DF, Flockhart DA.

Breast Cancer Res Treat. 2015 Nov;154(2):263-73. doi: 10.1007/s10549-015-3608-8. Epub 2015 Nov 4.

47.

Carboplatin with Decitabine Therapy, in Recurrent Platinum Resistant Ovarian Cancer, Alters Circulating miRNAs Concentrations: A Pilot Study.

Benson EA, Skaar TC, Liu Y, Nephew KP, Matei D.

PLoS One. 2015 Oct 20;10(10):e0141279. doi: 10.1371/journal.pone.0141279. eCollection 2015.

48.

Association of Variants in Candidate Genes with Lipid Profiles in Women with Early Breast Cancer on Adjuvant Aromatase Inhibitor Therapy.

Santa-Maria CA, Blackford A, Nguyen AT, Skaar TC, Philips S, Oesterreich S, Rae JM, Desta Z, Robarge J, Henry NL, Storniolo AM, Hayes DF, Blumenthal RS, Ouyang P, Post WS, Flockhart DA, Stearns V; Consortium on Breast Cancer Pharmacogenomics (COBRA).

Clin Cancer Res. 2016 Mar 15;22(6):1395-402. doi: 10.1158/1078-0432.CCR-15-1213. Epub 2015 Oct 13.

49.

Genotyping concordance in DNA extracted from formalin-fixed paraffin embedded (FFPE) breast tumor and whole blood for pharmacogenetic analyses.

Hertz DL, Kidwell KM, Thibert JN, Gersch C, Regan MM, Skaar TC, Henry NL, Hayes DF, Van Poznak CH, Rae JM.

Mol Oncol. 2015 Nov;9(9):1868-76. doi: 10.1016/j.molonc.2015.07.002. Epub 2015 Jul 29.

50.

Pooled Analysis of Six Pharmacologic and Nonpharmacologic Interventions for Vasomotor Symptoms.

Guthrie KA, LaCroix AZ, Ensrud KE, Joffe H, Newton KM, Reed SD, Caan B, Carpenter JS, Cohen LS, Freeman EW, Larson JC, Manson JE, Rexrode K, Skaar TC, Sternfeld B, Anderson GL.

Obstet Gynecol. 2015 Aug;126(2):413-22. doi: 10.1097/AOG.0000000000000927.

Supplemental Content

Loading ...
Support Center